
GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment
Betsy Goodfellow | November 27, 2023 | News story | Medical Communications | Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from a planned interim efficacy analysis of the phase 3 DREAMM-7 head-to-head trial which assessed Blenrep (belantamab mafodotin) as a second line treatment for relapsed or refractor multiple myeloma.
The trial met the primary endpoint of progression-free survival (PFS) as well as demonstrating that Blenrep combined with bortezomib plus dexamethasone (BorDex) significantly extended time to disease progression or death compared to standard-of-care treatment with daratumumab plus BorDex.
The safety and tolerability of the Blenrep treatment regimen remained consistent with the known safety profile of all drugs used in the trial.
Hesham Abdullah, senior vice president, global head Oncology, R&D at GSK, commented: “Patients with multiple myeloma need treatment options after first relapse that are efficacious, readily accessible and have novel mechanisms of action. We are particularly encouraged by the potential for belantamab mafodotin when combined with BorDex to address high unmet need in relapsed/refractory multiple myeloma, given the head-to-head comparison with the daratumumab-based standard of care regimen.”
Results from this interim analysis are expected to be presented at an upcoming scientific meeting as well as being shared with the relevant health authorities.
Betsy Goodfellow
Related Content

Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …

How will biomarker-led diagnostics reshape respiratory medicine?
By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …






